A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lonquex
Synonyms :
lipegfilgrastim
Class :
Haematopoietic Agents, Immunological Agent, Immunostimulants, Colony stimulating factors, recombinant human granulocyte colony-stimulating factor (G-CSF)
Brand Name :
Lonquex
Synonyms :
lipegfilgrastim
Class :
Haematopoietic Agents, Immunological Agent, Immunostimulants, Colony stimulating factors, recombinant human granulocyte colony-stimulating factor (G-CSF)
Dosage Forms & StrengthsÂ
Injectable solutionÂ
6 mg/0.6 mLÂ
lipegfilgrastim is used in patients who are on chemotherapy to reduce neutropenic complications with a dose of one 6 mg Lonquex, a single pre-filled syringe for only a single administration per cycle of chemotherapy, which is given one day after cytotoxic chemotherapy
Dose Adjustments
No data available or established
Safety and efficacy are not available or established in pediatrics.Â
Refer to the adult dosingÂ
may diminish the therapeutic effect when combined with lipegfilgrastim
may diminish the therapeutic effect when combined with lipegfilgrastim
may diminish the therapeutic effect when combined with lipegfilgrastim
may diminish the therapeutic effect when combined with lipegfilgrastim
may diminish the therapeutic effect when combined with lipegfilgrastim
may decrease the therapeutic effect when combined with lipegfilgrastim
may decrease the therapeutic effect when combined with lipegfilgrastim
myelosuppressive activities of lipegfilgrastim can increase if aldesleukin is used in combination
myelosuppressive activities of lipegfilgrastim can increase if alemtuzumab is used in combination
myelosuppressive activities of lipegfilgrastim can increase if carbamazepine is used in combination
may decrease the therapeutic effect of anti-neoplastic agents
may decrease the therapeutic effect of antineoplastic agents
may decrease the therapeutic effect of anti-neoplastic agents
may decrease the therapeutic effect of anti-neoplastic agents
it may increase the adverse effect when combined with aldesleukin
sipuleucel-T: they may decrease the therapeutic effect of immunostimulants
leflunomide: they may increase the immunosuppressive effect of immunostimulants
denosumab: they may increase the immunosuppressive effect of immunostimulants
baricitinib: they may enhance the immunosuppressive effect of immunostimulants
vincristine is known to increase the risk of peripheral neuropathy when combined with lipegfilgrastim
vinflunine is known to increase the risk of peripheral neuropathy when combined with lipegfilgrastim
may diminish the therapeutic effects of lipegfilgrastim
may diminish the therapeutic effects of lipegfilgrastim
cladribine: they may increase the immunosuppressive effect of immunostimulants
deucravacitinib: they may increase the immunosuppressive effect of immunostimulants
immunostimulants: they may increase the toxic effect of nadofaragene firadenovec
natalizumab: they may increase the immunosuppressive effect of immunostimulants
pimecrolimus: they may increase the immunosuppressive effect of immunostimulants
ruxolitinib: they may increase the immunosuppressive effect of immunostimulants
talimogene laherparepvec: they may increase the toxic effect of immunostimulants
tofacitinib: they may increase the immunosuppressive effect of immunostimulants
upadacitinib: they may increase the immunosuppressive effect of immunostimulants
antithymocyte globulin equineÂ
antithymocyte globulin: they may increase the toxic effect of immunostimulants
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
yellow fever vaccine: they may increase the toxic effect of immunostimulants
It may diminish the therapeutic efficacy when combined with pegloticase
lipegfilgrastim reduces the effectiveness of elapegademase when interacting with
pegvaliase reduces the effectiveness of lipegfilgrastim when interacting with
pegvisomant reduces the effectiveness of lipegfilgrstim when interacted
when both the drugs are combined, carmustine increases the effects of myelosuppression of lipegfilgrastim    
brincidofovir: they may decrease the therapeutic effect of immunostimulants
inebilizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ofatumumab: they may increase the immunosuppressive effect of immunostimulants
pidotimod: they may decrease the therapeutic effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
Actions and Spectrum:Â
Actions:Â
lipegfilgrastim is a second generation once per cycle first long-acting recombinant granulocyte colony-stimulating factor (G-CSF) which is a glycoprotein that is developed for patients who are receiving chemotherapy to reduce incidence of febrile neutropenia. lipegfilgrastim regulates the production and release of neutrophils from the bone marrow that are functional. Â
Spectrum:Â
lipegfilgrastim is a glycoprotein and long-acting recombinant human granulocyte colony-stimulating factor intended to reduce the chemotherapy induced neutropenia and incidence of febrile neutropenia. It is also used in the breast cancer chemotherapy induced neutropenia.  Â
Frequency Not DefinedÂ
ThrombocytopeniaÂ
LeukocytosisÂ
Hypersensitivity reactionsÂ
HypokalaemiaÂ
HeadacheÂ
Capillary leak syndromeÂ
Pulmonary adverse reactionsÂ
Skin reactionsÂ
Injection site reactionsÂ
Musculoskeletal painsÂ
Chest painÂ
Black Box Warning:Â
Effectiveness of this medication should not be measured with other drugs which falls under same class.
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
lipegfilgrastim is a second generation once per cycle first long-acting recombinant granulocyte colony-stimulating factor (G-CSF) which is a glycoprotein that is developed for patients who are receiving chemotherapy to reduce incidence of febrile neutropenia. lipegfilgrastim regulates the production and release of neutrophils from the bone marrow that are functional. Â
Pharmacodynamics:Â
Within 24 hours of administration of lipegfilgrastim there is an increase in peripheral blood neutrophil count and minor elevation of monocytes and lymphocytes which shows its stimulation for haemotopoietic progenitor cells and its differentiation into mature cells that are released into peripheral blood. It also shown to increase the antibacterial properties of neutrophils including phagocytosis.Â
Pharmacokinetics:Â
AbsorptionÂ
After SC administration of lipegfilgrastim the peak plasma concentrations was achieved after 30 -35 hours of time. Absorption of lipegfilgrastim is mainly via lymphatic and then into vascular system.Â
DistributionÂ
Lipegfilgrastim has a small weight-dependent Vd of 70 mL/kg which shows it is not distributed beyond vascular or lymphatic system.Â
MetabolismÂ
It is metabolized through intra or extra cellular degradation with the help of proteolytic enzymes which after bound to G-CSF receptors it is internalised by neutrophils within the cell by endogenous enzymes and degradation by neutrophil elastase extracellularly.Â
Elimination and ExcretionÂ
lipegfilgrastim has linear and non-linear clearance pathways. Median t1/2 is 33 hours.Â
Administration:Â
lipegfilgrastim is injected subcutaneously (SC) into the thigh, upper arm or abdomen and should be avoided in the areas where it is red, tender, or bruised or hard or that has stretch marks or scars. Â
First injection under the supervision of medical experts and self-administration only after enough motivation to the patients who becomes well motivated and adequately trained under the supervision of medical experts.Â
Patient information leafletÂ
Generic Name: lipegfilgrastimÂ
Why do we use lipegfilgrastim?Â
It is used in the patients who are undergoing chemotherapy to reduce the neutrophil complications and to reduce the incidence of febrile neutropenia which is administered after first cycle of cytotoxic chemotherapy.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
